9 / 21
Baseline Characteristics of the Efficacy and Safety Populations
Characteristics
Efficacy population (n=106)
Safety population (n=377)
Median age (range), years
59 (33–84)
62 (31–86)
Race, % (n)
White
78.3 (83)
80.1 (302)
Asian
6.6 (7)
5.8 (22)
Black or African American
3.8 (4)
2.1 (8)
Other
1.9 (2)
1.9 (7)
Missing
9.4 (10)
10.1 (38)
ECOG PS, % (n)
0
61.3 (65)
61.8 (233)
1
38.7 (41)
38.2 (144)
Cancer type, % (n)
Epithelial ovarian carcinoma
85.8 (91)
80.9 (305)
Fallopian tube carcinoma
8.5 (9)
8.8 (33)
Primary peritoneal carcinoma
5.7 (6)
10.3 (39)
Histological classification, % (n)
Serous
91.5 (97)
94.2 (355)
Mixed
†
4.7 (5)
2.9 (11)
Endometrioid
2.8 (3)
2.4 (9)
Clear cell carcinoma
0.9 (1)
0.3 (1)
Unknown
0
0.3 (1)
Median time since cancer diagnosis (range), months
51.7 (6.3–196.6)
42.7 (6.3–196.6)
BRCA
1/2 mutation type, % (n)
Germline
83.0 (88)
28.6 (108)
Somatic
17.0 (18)
7.4 (28)
Mutation of uncertain origin
0
1.9 (7)
No mutation (
BRCA
wild-type)
0
62.1 (234)
Oza AM et al.
Gynecol Oncol
. 2017;147:267–275